| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection P Lampertico, K Agarwal, T Berg, M Buti, HLA Janssen, ... Journal of hepatology 67 (2), 370-398, 2017 | 9887* | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1658 | 2018 |
| Treatment of acute hepatitis C with interferon alfa-2b E Jaeckel, M Cornberg, H Wedemeyer, T Santantonio, J Mayer, M Zankel, ... New England Journal of Medicine 345 (20), 1452-1457, 2001 | 1177 | 2001 |
| Treating viral hepatitis C: efficacy, side effects, and complications MP Manns, H Wedemeyer, M Cornberg Gut 55 (9), 1350-1359, 2006 | 939 | 2006 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 851 | 2021 |
| Natural killer cells act as rheostats modulating antiviral T cells SN Waggoner, M Cornberg, LK Selin, RM Welsh Nature 481 (7381), 394-398, 2012 | 690 | 2012 |
| Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J Jaroszewicz, BC Serrano, K Wursthorn, K Deterding, J Schlue, ... Journal of hepatology 52 (4), 514-522, 2010 | 611 | 2010 |
| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ... Liver International 31, 30-60, 2011 | 595 | 2011 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 564 | 2014 |
| Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper T Boettler, PN Newsome, MU Mondelli, M Maticic, E Cordero, M Cornberg, ... JHEP reports 2 (3), 100113, 2020 | 556 | 2020 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 486 | 2022 |
| Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report HLY Chan, A Thompson, M Martinot-Peignoux, T Piratvisuth, M Cornberg, ... Journal of hepatology 55 (5), 1121-1131, 2011 | 454 | 2011 |
| Update of the statements on biology and clinical impact of occult hepatitis B virus infection G Raimondo, S Locarnini, T Pollicino, M Levrero, F Zoulim, AS Lok, ... Journal of hepatology 71 (2), 397-408, 2019 | 430 | 2019 |
| The role of quantitative hepatitis B surface antigen revisited M Cornberg, VWS Wong, S Locarnini, M Brunetto, HLA Janssen, ... Journal of hepatology 66 (2), 398-411, 2017 | 419 | 2017 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 416 | 2014 |
| Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference M Cornberg, ASF Lok, NA Terrault, F Zoulim Hepatology 71 (3), 1070-1092, 2020 | 341 | 2020 |
| Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta B Heidrich, C Yurdaydın, G Kabacam, BA Ratsch, K Zachou, B Bremer, ... Hepatology 60 (1), 87-97, 2014 | 336 | 2014 |
| Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: the HEP‐NET acute‐HCV‐II study J Wiegand, P Buggisch, W Boecher, S Zeuzem, CM Gelbmann, T Berg, ... Hepatology 43 (2), 250-256, 2006 | 336 | 2006 |
| Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection C Sarrazin, T Berg, RS Ross, P Schirmacher, H Wedemeyer, U Neumann, ... Zeitschrift fur Gastroenterologie 48 (2), 289-351, 2010 | 311* | 2010 |
| Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients–FINITE study T Berg, KG Simon, S Mauss, E Schott, R Heyne, DM Klass, C Eisenbach, ... Journal of hepatology 67 (5), 918-924, 2017 | 296 | 2017 |
Heiner WedemeyerDept. oGastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical SchoolEmail verificata su mh-hannover.de
